Member LoginDividend CushionValue Trap |
Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for
any changes.
Nov 7, 2017
Analysis of Spark Energy (SPKE) and Brighthouse Financial (BHF)
Let's talk about an extremely risky microcap energy equity and a unique potential value opportunity in the insurance industry, Brighthouse Financial, the spinoff of Metlife. Nov 3, 2017
Dividend Increases/Decreases for the Week Ending November 3
Let's take a look at companies raising/lowering their dividends this week. Nov 2, 2017
The Price of Good Investment Research?
Photo credit: Phlebotomy Tech; Thomas Haynie Skimping on research could cost you big when the you-know-what hits the fan. Research firms are reportedly charging as much as $5,000 per hour for one-on-one meetings with top analysts. Access to basic research is now being priced at $40,000 a year at some firms. Oct 31, 2017
Novartis Gearing Up for Growth
Image Source: Novartis. Dividend Growth Newsletter portfolio idea Novartis continues to grow its free cash flow stream while producing a string of products still in the infancy of their respective growth curves. The pharma/biotech realm remains bedeviled with patent issues that can disrupt cash flow generation once protection is lost, causing us to look for companies positioned for a fresh leg of growth. To that end, let’s take a look at Novartis’ pipeline, near-term potential, and how it relates to its dividend health. Oct 29, 2017
Dividend Increases/Decreases for the Week Ending October 27
Let's take a look at companies raising/lowering their dividends this week. Oct 27, 2017
Analysis of Aspen Technology (AZPN) and IPG Photonics (IPGP)
Image Source: Aspen Tech. Aspen Technology helps some of the most capital-intensive industries optimize asset performance via process modeling, big data machine learning, and analytics, and its very own asset-light operations help it generate impressive levels of free cash flow. Shares aren’t cheap, however (it is trading above our fair value estimate range), and current price levels imply one hefty price-to-earnings ratio. Still, it’s hard not to like Aspen Technology’s high-ROIC business model, with the company garnering one of the highest Economic Castle ratings in our coverage. IPG Photonics is home to an impressive portfolio of high-performance fiber lasers and similar technologies that are used in materials processing, advanced communications, and medical applications--areas and applications that are expected to experience strong growth in coming years. We think IPG Photonics’ degree of vertical integration, IP portfolio, and process expertise offer it a number of competitive advantages. The company boasts a GAAP operating margin in the mid-30s and has generated impressive free cash flow expansion in recent years, but shares aren’t cheap either (it is trading at the high end of our fair value estimate range). Customer concentration and expansion into unproven markets add a layer of risk. Oct 27, 2017
Intel Could Become a $50+ Stock?
Image Source: Intel. Fundamental momentum at Intel is phenomenal. The company is putting up record quarterly performance, and traditional multiple analysis suggests Intel could be priced north of $50 per share. It also offers a very attractive dividend yield. Oct 26, 2017
Risky Restaurants? Taking a Look at Chipotle and Domino’s Pizza
Image Source: Valuentum. Chipotle and Domino’s Pizza have very little in common, in our view, but let’s take a look at what has been causing volatility in each company’s stock of late. Oct 25, 2017
Does Visa Ever Disappoint?
Image Source: Visa. The credit card company's stock hit an all-time high on the trading session October 25. We continue to be huge fans of the company’s fundamentals. Oct 25, 2017
Key Oncology Assets Powering Johnson & Johnson Higher
Image Source: Johnson & Johnson. Shares of newsletter portfolio holding Johnson & Johnson continue their stellar run, posting new all-time highs on the heels of an impressive third quarter earnings report. Let’s take an in-depth review of key pharma product franchises as they relate to the performance of the stock.
prev12345678910111213141516171819202122232425
26272829303132333435363738394041424344454647484950 51525354555657585960616263646566676869707172737475 767778798081828384858687888990919293949596979899100 101102103104105106107108109110111112113114115116117118119120 121122123124125126127128129130131132133134135136137138139140 141142143144145146147148149150151152153154155156157158159160 161162163164165166167168169170171172173174175176177178179180 181182183184185186187188189190191192193194195196197198199200 201202203204205206207208209210211212213214215216217218219220 221222223224225226227228229230231232233234235236237238239240 241242243244245246247248249250251252253254255256257258259260 261262263264265266267268269270271272273274275276277278279280 281282283284285286287288289290291292293294295296297298299300 301302303304305306307308309310311312313314315316317318319320 321322323324325326327328329330331332333334335336337338339340 341342343344345346347348349350351352353next The High Yield Dividend Newsletter, Best Ideas
Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on
this website are for information purposes only and should not be considered a solicitation to buy or sell any
security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s
accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or
omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts
no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a
registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees,
and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.
|